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overall survival: 99,1% (1 group) vs. 97,7% (2 group) and 97,8% (3 
group), (p< 0.216). Five-year event free survival: 98,0% (1 group) vs. 
92,2% (2 group)and 94,5% (3 group), (p < 0.0345). Only 8% of the 
patients of the 1 group developed grade 2 erythema , 17,7% of the 
patients of the 2 group (p=0.043) and 14,3% of the patients of the 3 
group (p<0,048). Side effects after 5 years: 35,7% (1 group) vs. 53,8% 
(2 group) and 42,8% (3 group), (p < 0.05). Excellent and good cosmetic 
results after 5 years: 79,4% (1 group) vs. 65,4% (2 group) and 73,6% (3 
group), (p < 0.049). 
Results: No difference in distant metastasis and overall survival 
between different regimes of RT. 
Conclusions: Accelerated hypofractionated RT (3 Gy per fraction over 
2,5 weeks, total dose of 39Gy) decrease in local relapse, acute 
toxicity and adverse effects, increase five-year event free survival and 
cosmetic results after accelerated hypofractionated vs. dynamic 
hypofractionated and standard radiation treatment.  
   
EP-1062   
Acute and early late toxicity in patients treated with 
hypofractionated RT for early breast cancer: our experience 
V. Borzillo1, A. Argenone1, S. Falivene1, D. Cianniello2, M. D'Aiuto3, P. 
Muto1 
1Istituto Nazionale Tumori Fondazione Pascale, Radiotherapy, Napoli, 
Italy  
2Istituto Nazionale Tumori Fondazione Pascale, Breast Oncology, 
Napoli, Italy  
3Istituto Nazionale Tumori Fondazione Pascale, Breast Surgery, 
Napoli, Italy  
 
Purpose/Objective: Whole breast irradiation(WBI) (50 Gy in 25 daily 
fractions of 2 Gy over 5 weeks ± boost of 10 Gy to the tumor bed) is 
the standard treatment after breast-conserving surgery (BCS) for early 
breast cancer (EBC). Recent randomized trials have confirmed that 
hypofractionated whole breast irradiation (WB-HyRT) is an effective 
alternative to conventional WBI for its equivalence in terms of local 
tumorcontrol, patients survival and late post-radiation effects. The 
aim of our experience was to evaluate feasibility, compliance and 
acute and early late toxicity of WB-HyRT. 
Materials and Methods: From February 2011 to November 2012, 41 
patients with EBC (pT1-2, pN0-1, pM0), who underwent BCS and 
sentinel nodal examination with or without axillary dissection, were 
treated with adjuvant WB-HyRT using 3D conformal radiotherapy. The 
median age was 73 years (range 60-84). The whole breast was treated 
with two opposed tangential fields, for a total dose of 42.56 Gy in 16 
daily fractions (2.66 Gy/f), with Linac 6 MV. Five patients received 
chemotherapy antracicline and taxan based, before RT. 36 patients 
received adjuvant hormonal therapy (FATA protocol), because the five 
remaining cases had hormone receptors negative. Toxicity was 
evaluated according to RTOG/EORTC toxicity criteria. The acute 
toxicity (within 6 months after the end of RT) was evaluate during RT 
course with weekly clinical examination, and early late toxicity wase 
stimated during standard follow-up.  
Results: the mean follow-up was 9 months (1-21 range). All patients 
completed radiotherapy without break for toxicity end with a good 
compliance to the treatment. All patients were evaluated for acute 
toxicity and 21 for early late toxicity. Acute skin toxicity was G3 in 1 
patient (2,4%), G2 in 6 pts (14,6%), G1 in 26 pts (63,4%) and G0 in 8 
pts (19,5%). Acute hematological toxicity was G3 in 2 pts (5%), G1 in 3 
pts (7,3%), G0 in 36 pts (87,7%) and none G2. None patients suffered 
from cardiac or pulmonary or other acute toxicity. Early late skin 
toxicity observed was G1 in 5 pts (23,8%) and G0 in16 pts (76,2%). 
Only one (4,2%) patient had G1 early late hematological toxicity. No 
other early late toxicity were register. 
Conclusions: Our results showed that WB-HyRT is feasible and well 
tolerated, with few acute and early late toxicity and good compliance 
to the treatment. In older women with EBC the hypofractionated 
schedule represent a biologically acceptable alternative to the 
traditional 6 weeks regime. Also the reduction of the overall 
treatment time leads advantages in economic saving terms and can 
have a benefit in LINAC waiting list too. 
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Purpose/Objective: Whilst 3dCRT is widely used for the adjuvant 
treatment of breast cancers, the use of ARC therapy using Helical 
Tomotherapy(HT) is gaining momentum in specific centres. 
Materials and Methods: Two Radiotherapy(RT) plans (HT and 3DCRT) 
for ten adjuvant chest wall and breast including supraclavicular fossa 
(SCF) treatment were compared. Dose to target volumes (TV) 
including SCF (2 with gross nodes requiring boost), internal mammary 
chain(IMC, 3 patients), lung,heart, brachial plexus were compared. 
Homogeneity index (HI) and conformityindex (CI) was calculated for 
TV coverage. A hypofractionated 40Gy in 15fraction schedule was 
prescribed to the PTV.  
Results: TV coverage both for chest wall and whole breast(n=2) was 
better with HT; median dose (±SD) of 41.58Gy (±1.92) for HT and 
38.97(±3.41)using 3DCRT; p=0.01. SCF median dose 41.62Gy (±2.85) 
vs. 31.86Gy (±12.34)respectively (p-0.04) was better with HT whilst 
IMC coverage too was betterwith HT. HI and CI were both better with 
HT than 3dCRT. Brachial plexus received higher maximum 
(41.31Gy/33.99Gy) and median dose (17.34Gy/4.96Gy) with HT. The 
mean dose to the heart was higher with HT than 3DCRT; 5.65Gy versus 
0.79Gy for right sided tumours(n=4) and 9.69Gy vs.1.69Gy for left 
sided tumours(n=6) without IMC coverage(n=3) and 11.56 Gy vs.2.34 
Gy for left sided tumours with IMC coverage(3DCRT plans generated 
without IMC coverage). For left sided tumours with IMC irradiation, 
the V15Gy and V20Gy(mean±SD) of the heart was significantly higher 
with HT (24.55±12.18% vs.4.35±1.95% and 15.83±9.51 vs.3.96±1.78%) 
respectively..Those without IMC coverage,the mean V15Gy and V20 Gy 
of heart was 21.62% vs.5.38% and 10.42% vs.4.82% respectively. 
Contralateral mean lung dose was also higher with HT (3.38Gy 
vs.0.22Gy).Mean V5Gy and V15Gy of contralateral lung was 19.17% 
vs.0% and 1.3% vs. 0% respectively in HT versus 3dCRT. The opposite 
breast too received a higher mean dose with HT than 3DCRT (7.02Gy 
vs. 0.26Gy) 
Conclusions: HT provided a better target volume coverage including 
coverage of IMC and SCF and Breast/Chest wall without the use of 
field junctions. The better CI with HT was achieved at the expense of 
higher mean dose to the OARs like heart, contralateral lung, opposite 
breast and brachial plexus. Dosimetric data suggests little evidence 
for the routine use of HT in adjuvant breast radiotherapy but it could 
be considered in selected complex volumes including when treating 
the IMC, SCF and boosting gross residual disease post chemotherapy. 
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Purpose/Objective: Localization of the tumor bed of breast cancer is 
crucial for accurate planning of boost irradiation. Lumpectomy cavity 
and surgical clips provide localizing information about tumor bed. 
However, defining the tumor bed is often difficult because of 
presence of unclear lumpectomy cavity and lack of certain 
information such as absence of surgical clips. In the present study, we 
evaluated the role of diagnostic PET-CT in localization of the tumor 
bed using deformable image registration (DIR). 
Materials and Methods: We selected twenty-five patients who had a 
preoperative PET-CT performed and underwent breast-conserving 
surgery with surgical clips in tumor bed. In every individual patient, 
two target volumes were separately delineated on planning CT; 1) 
planning target volume based on surgical clips with a margin of 1 cm 
(PTVclip) and 2) gross tumor volume based on 90% of maximum SUV on 
PET-CT registered by DIR (GTVPET). The percent of GTVPET in PTVclip 
(Vin) was calculated and distance between center points of two 
volumes (Dcenter) was also measured. 
Results: Mean Dcenter between two volumes was 1.4 cm (range, 0.33 – 
2.53). Mean Vin was 94.8% (range, 60.9-100) and 100% in 18 out of 25 
patients. When compared to the center of PTVclip, the center of GTVPET 
tended to be located posteriorly (mean 0.3 cm, standard deviation 
0.6), laterally (mean 0.3cm, standard deviation 0.8) and inferiorly 
(mean 0.4 cm, standard deviation 0.9). 
Conclusions: DIR of diagnostic PET-CT can be a considerable 
reference for the localization of tumor bed on planning CT for breast 
cancer radiotherapy. 
 
 ELECTRONIC POSTER: CLINICAL TRACK: GASTRO-
INTESTINAL TUMOURS (UPPER AND LOWER GI)  
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Purpose/Objective: To evaluate acute and late injury of kidney in 
radiotherapy of patients with gastric cancer. 
Materials and Methods: Twenty patients with gastric cancer that 
were treated with post operative chemoradiation were prospectively 
evaluated. Chemotherapy was done with 5FU and LV (400 mg/m2 5FU, 
30 mg/m2 LV) in 4 first and 3 last days of radiotherapy.Total radiation 
dose of 45 Gy was delivered in 25 fractions (5 days a week) with 1.8 
Gy dose per fraction by 2 opposed fields. In this study, decrease of 
glomerular filtration rate (GFR) value was used for definition of 
toxicity. The GFR value be measured using 99mTc-diethylene 
triaminepentaacetic acid (DTPA) scan that was done for all of the 
patients before, during (in 15thsession of radiotherapy) and 3 to 9 
months after radiotherapy. The imaging was done using dual head 
gamma camera. 
Results: There was a significant reduction in the GFR values of 
irradiated kidneys. 
Conclusions: 99mTc-DTPA scan can be a suitable modality for 
determining of renal toxicity after radiotherapy of gastric cancers. 
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Purpose/Objective: We report initial experience with CyberKnife (CK) 
in patients hepatocellular carcinoma (HCC), liver metastasis (LM) and 
Klastkin tumour (KT).  
Materials and Methods: Seventeen consecutive patients (mean age 
57.5 years, range 35-81 yrs; 82% male) treated with fiducial based 
robotic radiosurgery. Nine patients had HCC (n=9) and four each had 
LM (n=4) and KT (n=4). 11/17 patient (70%) were with Child Pugh 
A/B,8/9 with HCC had infective hepatitis (4 each with hepatitis B & 
C), 5/17(29%) had diffuse cirrhosis, 70%(12/17) had single lesion in 
liver and target volume 90 cc in 6 (35%)patients respectively. 13/17 
(75%) patients had prior treatment [chemotherapy8/13 (61%), TACE 
5/13 (39%)] and treated with SBRT on progression. All patients were 
treated with 3 fractions (21-45Gy/3#; mean dose 33Gy, prescription 
isodose84%, target coverage 94%); fiducial tracking based CK. Mean CI, 
nCI, HI was1.13, 1.28 and 1.19 respectively. Mean liver dose was 4.7 
Gy, 800cc liver dose 8.2 Gy; 2% small intestine dose 10.6 Gy. Mean 
nodes, beamlets, monitor units and treatment time 69, 174, 46919 
and 60.4 min respectively. 
Results: At mean follow up of 11.3 months (range 1.9-26.5), 12/17 
(70%) patients expiredand 5/17 (30%) alive (3 patient with controlled 
primary, one each with local progression and metastasis). Median 
overall survival (OS) in HCC patients was11.9 months (2.1-26.5 
months), MT 8.3 months (1.9-13.3 months) and KT was 12.8 months 
(7.4-25 months) respectively. 5/17 (30%) patients had grade I-II GI 
toxicities, no grade III-IV toxicities were observed and only one 
patient (12%) had anicteric ascites with high serum alkaline 
phosphatase two months after CK and recovered with supportive care. 
Median OS (month) were significantly influenced by factors such as 
performance status (KPS 70-80 vs 90-100: 8.3 vs 15.4; p=0.034), Child 
Pugh (CPA/B vs C: 13.3 vs 4.9; p=0.039), cirrhosis (only fatty liver vs 
diffusecirrhosis: 13.3 vs 9.4; p=0.005), prior treatment (no Rx vs prior 
Rx: 16.6 vs8.3; p=0.006), dose (39Gy: 9.5 vs 15.4; p=0.02) and target 
volume (90 cc: 15.7 vs 7.7; p=0.011) respectively. There was no 
fiducial related toxicity or migration. 
Conclusions: CyberKnife is safe and effective local treatment 
modality in selected patients with liver malignancies with minimal 
adverse events. Factors such as performace status, Child Pugh 
classification, cirrhosis status, prior treatment, RT dose andtarget 
volume significantly influence survival function. 
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Purpose/Objective: To assess the outcome of non metastatic 
esophagus cancer according to therapeutic strategy: evolution of 
esophagus cancer after curative treatment, results and toxicities of 
combined treatments and factors which can influence disease local 
control, disease-free and overall survival. 
Materials and Methods: 120 patients with exclusive 
radiochemotherapy (RC) and possibly surgery between 2004 and 2010 
treated esophagus cancer were retrospectively studied. The first site 
of relapse was classified as follows: local (tumor), locoregional (tumor 
and/or nodal: coeliaq, mediastinal, sus-clavicular) or metastatic. 
Patients had TEP-FDG before performing treatment to help for GTV 
delineation. 
Results: With a 15,7 months (1,4-62) median follow-up, there was 89 
deaths and 77 recurrence.Three types of treatments were performed: 
50 Gray (Gy) exclusive radiochemoterapy (RC) (47 patients) or 50 to 
65 Gy exclusive RC (44 patients) or RC followed by surgery (27 
patients). RC was performed after surgery for 2 patients. Local first 
relapse was as much frequent as distance relapse (50 patients). With 5 
cm marging up and down to the tumor, there was only one beam 
border nodal relapse. Two-year survival was 39,5% (95% confidence 
interval [IC]: 30,5-40,8) and relapse-free survival was 26,5% (IC: 18,6-
35). Multivariate analysis has revealed that treatment type and 
disease stade had a significant impact on survival, relapse-free 
survival and locoregional control. Compared to exclusive RC, surgery 
improved locoregional control (40,2 versus 8.7 months, p=0.0004) but 
in a younger population. Despite post-operative mortality, the gain 
was maintained for distance relapse-free survival (40.2 versus 10 
months, p=0.0147)and overall survival (29.3 versus 14.2 months, 
p=0.0088). Compared to 50 Gy RC, local control was improved if high 
dose RC was performed (13.8 versus 7.5 months, p=0.05) but not 
overall survival (14.0 versus 15.4 months, p=0.24). Incidence of late 
grade 3 treatment toxicity was not different between three arms 
(p=0.007). 
Conclusions: Despite multidisciplinary care, esophagus cancer 
pronostic is still poor. More than one third relapse was local. 
Locoregional control was better with high dose RC. Surgery, 
performed in selected patients only, improved locoregional control, 
relapse-free disease and overall survival. With only one beam border 
recurrence, nodal elective irradiation seemed to be not usefull. These 
results have to be confirmed by a soon opening phase III dose 
escalation EqualEstro approved study: Concorde. 
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Purpose/Objective: Chemotherapy (CT) is confirmed to prolong 
survival in metastatic and inoperable locally advanced gastric 
carcinoma as compared to the best supportive care. Earlier in 
retrospective study we’d shown radiotherapy and chemoradiation 
(CRT) were superior to chemotherapy in terms of overall survival. In 
the present study we analyze preliminary results of one-center 
randomized trial to compare chemoradiation with chemotherapy for 
inoperable, locally advanced gastric carcinoma (ILAGC). 
Materials and Methods: Beginning from January, 2010 patients with 
ILAGC were prospectively randomized to CT or CRT. Inclusion criteria 
were histological confirmation of GC, absence of evident metastatic 
disease, general condition 0-2 by ECOG scale, dysphagia 0-1, and 
normal laboratory tests. In CRT group the treatment was started from 
2D irradiation to 60 Gy, 30 fractions: initially, from two parallel-
opposed fields encompassing both primary and regional lymphatics 
with shielding of kidneys, then last ten fractions were delivered to 
primary only, isocentrically, evading spinal cord. Chemotherapy being 
the same in both groups consisted of Cisplatinum 100 mg per m2 D1 
and 24 h infusion of 5-Fluorouracil 1000 mg per m2 D1-5 every four 
weeks, up to 6 courses. Primary endpoint was overall survival, 
calculated as a time gap between the start of treatment and death 
from any reason. The distribution by initial characteristics and survival 
were compared using chi-square and log-rank methods respectively. 
Results: At the moment of analysis 59 patients with ILAGC were 
randomized, 29 for CRT, 30 to CT. Twenty four (59%) pts died, 9 pts 
are continuing treatment, median follow-up is 14 months. Forty six 
(78%), 44 (75%) and 49 (83%) patients had Stage 3 (TNM 7), T4 and 
exploratory surgery, respectively. The distribution on basic initial 
parameters was similar. The total dose of at least 50 Gy delivered to 
